ArticleBiology2025
scRL: Utilizing Reinforcement Learning to Evaluate Fate Decisions in Single-Cell Data.
Article in Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial Intelligence in Transcriptomics: From Human-in-the-Loop to Agentic AI.Journal of personalized medicine · 2026Review
- ScGeo reveals non-canonical trajectories beyond RNA velocity in radiation-induced hematopoietic recovery.Bioinformatics advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Single-cell RNA sequencing now profiles whole transcriptomes for hundreds of thousands of cells, yet existing trajectory-inference tools rarely pinpoint where and when fate decisions are made. We present single-cell reinforcement learning (scRL), an actor-critic framework that recasts differentiation as a sequential decision process on an interpretable latent manifold derived with Latent Dirichlet Allocation. The critic learns state-value functions that quantify fate intensity for each cell, while the actor traces optimal developmental routes across the manifold. Benchmarks on hematopoiesis, mouse endocrinogenesis, acute myeloid leukemia, and gene-knockout and irradiation datasets show that scRL surpasses fifteen state-of-the-art methods in five independent evaluation dimensions, recovering early decision states that precede overt lineage commitment and revealing regulators such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.